By Tom Whitfield

Arcutis Biotherapeutics has presented new ZORYVE cream data in infants with eczema, Investing.com Canada reported Friday.

ZORYVE cream 0.15% is a once-daily topical PDE4 inhibitor. The FDA approved it for atopic dermatitis in 2024 in patients 6 and older. The new infant data point to Arcutis's push into a younger population with very few non-steroidal topical options.

The Investing.com Canada report didn't include specific efficacy endpoints, sample size, or investigator commentary. The presentation signals a clear pediatric supplemental NDA (sNDA) strategy. Arcutis has used that pathway twice before, in 2023 and 2024.

Why does the infant population matter?

Atopic dermatitis affects roughly 10-20% of children worldwide, with most cases starting before age 5. Infants with eczema pose a particular treatment challenge for pediatricians.

Topical corticosteroids remain the workhorse. But caregivers worry about long-term skin thinning, systemic absorption, and HPA-axis suppression on small patients with high body-surface-area ratios.

That worry has driven steady demand for non-steroidal topicals. Crisaborole 2% ointment (Eucrisa), another PDE4 inhibitor, won FDA approval in 2016 for patients 3 months and older. Adoption has stayed limited by application site pain and stinging reported in clinical trials.

The American Academy of Dermatology's 2023 atopic dermatitis guidelines list topical corticosteroids and crisaborole as the primary options for infants. Topical calcineurin inhibitors carry a boxed warning in this age group. That leaves clinicians with limited non-steroidal choices for moderate-to-severe disease.

What is the ZORYVE opportunity?

Arcutis built its commercial franchise around the once-daily, steroid-free cream. Roflumilast works by inhibiting phosphodiesterase-4, an enzyme that breaks down cyclic AMP, reducing inflammatory cytokine release in skin. The compound failed twice in oral COPD pivotal trials before its 2011 approval, branded Daliresp. The topical formulation launched in 2022 in plaque psoriasis.

ZORYVE's atopic dermatitis label came in 2024, with seborrheic dermatitis following in late 2023. That made it the first PDE4 inhibitor approved in seb derm. The AD launch followed the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials, which enrolled more than 1,300 patients 6 and older. Validated IGA and EASI endpoints supported the 2024 FDA decision.

The current ZORYVE atopic dermatitis label lists the most common adverse reactions as headache (1.5%), nausea (1.5%), and application site pain (1.0%). That profile, if it holds in infants, would be a meaningful selling point against crisaborole's site-reaction reputation.

Extending into infants would widen the addressable population. It would also put ZORYVE in direct competition with crisaborole for the under-6 segment. Investors and dermatologists will look first at safety, since infant skin permeability differs sharply from older children's, and the PDE4 class has historically raised ocular and gastrointestinal concerns.

What did the report actually say?

The Investing.com Canada item carried no link to the original Arcutis press release, no EASI or IGA endpoints, and no named investigator. It also didn't say whether the findings came from a pivotal trial, a pooled analysis, or a real-world cohort. The publication date and venue of the presentation weren't specified.

Derm Field has requested the full data set from Arcutis. We'll update this story when the company responds.

What happens next?

If the data show acceptable safety and meaningful itch or lesion reduction in infants under 2, Arcutis is likely to file a pediatric sNDA with the FDA in 2025 or 2026. The first non-steroidal topical to win an under-6 label will set the bar for every subsequent entrant. Pediatricians will want head-to-head data against crisaborole before switching. The market segment has seen essentially no new non-steroidal topical approvals in nearly a decade.